BioSpace News Archive

Avalo Therapeutics, Inc. announced a 1-for-240 reverse stock split of the Company’s common stock, par value $0.001, which will be effective at 5:00 pm Eastern Time on December 28, 2023.

Algernon Pharmaceuticals Inc. a Canadian clinical stage pharmaceutical development company announces an increase to its non-brokered private placement, previously announced on December 12, 2023, from gross proceeds of $150,000 to $280,000 of units at an issue price of $0.075 per Unit.

Novocure announced that management will participate in the 42nd Annual J.P. Morgan Healthcare Conference on January 9-10, 2024. William Doyle, Novocure’s Executive Chairman, will speak on behalf of the company and address questions from analysts at 7:30 a.m. PST on Wednesday, January 10, 2024.

Zevra Therapeutics, Inc. a rare disease therapeutics company, announced it resubmitted its New Drug Application for arimoclomol, an investigational therapeutic candidate for the treatment of Niemann-Pick disease type C to the U.S. Food and Drug Administration on December 22, 2023.

Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. and a clinical stage biotechnology company developing ultra-high concentration nitric oxide as an immunotherapeutic for solid tumors, announced that the Phase 1 Study evaluating UNO in advanced, relapsed or refractory unresectable, primary or metastatic cutaneous and subcutaneous solid tumors has cleared the first cohort of 25,000 ppm single dose UNO by the Safety Review Committee with no reported dose limiting toxicities.